Press release
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Investor Notice: Investigation of Takeover by AbbVie Inc
An investigation on behalf of investors of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE).
Investors who purchased shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) and currently hold any of those NASDAQ: CERE shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain officers and directors of Cerevel Therapeutics Holdings, Inc. breached their fiduciary duties owed to NASDAQ: CERE investors in connection with the proposed acquisition.
Cambridge, MA based Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. On December 06, 2023, AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) announced an agreement under which AbbVie will acquire Cerevel Therapeutics. Under the terms of the transaction AbbVie Inc. (NYSE: ABBV) will acquire all outstanding Cerevel Therapeutics (NASDAQ: CERE) common stock for $45.00 per share in cash.
However, the investigation concerns whether the offer is unfair to NASDAQ: CERE stockholders. More specifically, the investigation concerns whether the Cerevel Therapeutics Holdings, Inc. Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
Those who are current investors in Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) shares have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Investor Notice: Investigation of Takeover by AbbVie Inc here
News-ID: 3478027 • Views: …
More Releases from Shareholders Foundation, Inc.
First Solar, Inc. (NASDAQ: FSLR) Investor Alert: Deadline in Lawsuit on August 2 …
A deadline is coming up on August 24, 2026 in the lawsuit filed for certain investors of First Solar, Inc. (NASDAQ: FSLR) over alleged securities laws violations by First Solar, Inc.
Investors who purchased shares of First Solar, Inc. (NASDAQ: FSLR) have certain options and there are strict and short deadlines running. Deadline: August 24, 2026. First Solar, Inc. (NASDAQ: FSLR) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
Verra Mobility Corporation (NASDAQ: VRRM) Long Term Investor Alert: Investigatio …
An investigation on behalf of current long-term investors in shares of Verra Mobility Corporation (NASDAQ: VRRM) concerning potential breaches of fiduciary duties by certain directors and officers of Verra Mobility Corporation (NASDAQ: VRRM was announced.
Investors who are current long term investors in Verra Mobility Corporation (NASDAQ: VRRM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law…
Hub Group, Inc. (NASDAQ: HUBG) Investor Alert: Deadline in Lawsuit on August 28, …
A deadline is coming up on August 28, 2026 in the lawsuit filed for certain investors of Hub Group, Inc. (NASDAQ: HUBG) over alleged securities laws violations by Hub Group, Inc.
Investors who purchased shares of Hub Group, Inc. (NASDAQ: HUBG) have certain options and there are strict and short deadlines running. Deadline: August 28, 2026. Hub Group, Inc. (NASDAQ: HUBG) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
Planet Fitness, Inc. (NYSE: PLNT) Investor Alert: Deadline in Lawsuit on Septemb …
A deadline is coming up on September 14, 2026 in the lawsuit filed for certain investors of Planet Fitness, Inc. (NYSE: PLNT) over alleged securities laws violations by Planet Fitness, Inc.
Investors who purchased shares of Planet Fitness, Inc. (NYSE: PLNT) have certain options and there are strict and short deadlines running. Deadline: September 14, 2026. Planet Fitness, Inc. (NYSE: PLNT) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call…
More Releases for Cerevel
Dopamine Agonists Market is expected to reach US$ 1,732.41 Million by 2033 | Eme …
Market Size and Growth:
The Dopamine Agonists Market size reached US$ 1,148.88 Million in 2024 and is expected to reach US$ 1,732.41 Million by 2033, growing at a CAGR of 5.4 % during the forecast period 2025-2033.
The Dopamine Agonists Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed…
Parkinson's Disease Pipeline Analysis, 2025 by DelveInsight | Annovis Bio, Cerev …
DelveInsight's, "Parkinson's disease - Pipeline Insight, 2025" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Parkinson's disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that the Parkinson's Disease pipeline includes over 130…
Panic Disorder Market on Track for Major Expansion by 2032, According to DelveIn …
DelveInsight's "Panic Disorder Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Panic Disorder, historical and forecasted epidemiology as well as the Panic Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Panic Disorder, offering comprehensive insights into the Panic Disorder revenue trends, prevalence, and treatment landscape. The…
Parkinson's Disease Clinical and Non-Clinical Studies, Key Companies, Therapeuti …
DelveInsight's, "Parkinson's Disease- Pipeline Insight, 2025" report provides comprehensive insights about 130+ companies and 150+ pipeline drugs in Parkinson's Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, over 130 prominent companies are actively involved in…
Panic Disorder Market Statistics Expected to Experience Major Growth by 2032, Ac …
The Key Panic Disorder Companies in the market include - Pfizer, Honeybrains Biotech LLC, Cerevel Therapeutics, Massachusetts General Hospital, Samsung Medical Center, Indiana University, UCB Pharma, and others.
DelveInsight's "Panic Disorder Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Panic Disorder, historical and forecasted epidemiology as well as the Panic Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and…
Parkinson's disease Market to Witness Growth by 2032, Estimates DelveInsight | C …
(Albany, USA) DelveInsight's "Parkinson's disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Parkinson's disease, historical and forecasted epidemiology as well as the Parkinson's disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Parkinson's disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Parkinson's disease…
